A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Sparsentan (FILSPARI)

Endothelin Receptor Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2023-02-17
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$48.4M in CY2024 Part D spend4K claims · 767 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
64 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Sparsentan used for?

Sparsentan is a Endothelin Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Sparsentan?

No. Sparsentan is brand-only with no generic equivalents currently in market.

How much does my plan pay for Sparsentan?

NADAC pricing data not currently available for this drug.

Is Sparsentan on the FDA shortage list?

No. Sparsentan is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Endothelin Receptor Antagonist5 alternatives in D1
01
Ambrisentan
Brand: Letairis
$8.34Lowest NADAC
8Generic mfrs
$364.6MCY24 Part D spend
Compare →
02
Aprocitentan
Brand: TRYVIO
Lowest NADAC
0Generic mfrs
$77,158CY24 Part D spend
Compare →
03
Bosentan
Brand: Tracleer
Lowest NADAC
4Generic mfrs
$48.1MCY24 Part D spend
Compare →
04
Macitentan
Brand: OPSUMIT
Lowest NADAC
5Generic mfrs
$1.87BCY24 Part D spend
Compare →
05
Macitentan and Tadalafil
Brand: OPSYNVI
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.